Doximity Stock Surges 180% on Strong Q3 Guidance and Growth Outlook

Key Facts

In a move reflecting a potential inflection point for the company's growth trajectory, Doximity stock experienced an extraordinary surge of over 180% in pre-market trading. This momentum followed the release of its fiscal Q1 2027 results, which signaled significant optimism regarding future performance. According to reports, the massive price action underscores a strong market reaction to the company's revised financial outlook.

The current bullish sentiment is primarily driven by management raising its Q3 revenue guidance to a midpoint of $170.5 million, approximately 13% above consensus estimates. This significant upward revision suggests an acceleration in business growth following a period of slowing performance, leading investors to re-rate the stock based on the new data provided in the earnings report.

Regarding price action, DOCS shows a strong upward trend, though specific closing price levels were unavailable as of August 7, 2026. Traders should watch for price consolidation in upcoming sessions while monitoring broader US economic catalysts, such as the ISM Manufacturing PMI and JOLTs Job Openings scheduled for early August, which may influence risk appetite in the growth and tech sectors.